Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.31 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21718950 | 0.80 | S1PR1 (0.38) | HTTKMT2AHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL21719002 | 0.80 | KMT2A (0.46) | HTTKMT2AHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL16394692 | 0.80 | HTT (0.41) | HTTKMT2APTGDR2SMN1; SMN2HSD17B10 | |
| SCHEMBL15612623 | 0.77 | PTGDR2 (0.39) | PTGDR2KDM4EALDH1A1ALOX15 | |
| SCHEMBL21718931 | 0.77 | HTT (0.34) | HTTKMT2AHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL21718921 | 0.77 | PLAU (0.42) | HTTKMT2AHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL31143948 | 0.77 | CTSD (0.38) | HTTKMT2APTGDR2SMN1; SMN2HSD17B10 | |
| SCHEMBL16302764 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2HSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL13253377 | 0.76 | HSP90AA1 (0.36) | SMN1; SMN2KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL22949453 | 0.74 | L3MBTL1 (0.33) | HTTKMT2AHPGDSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | HTT 3512/4885KMT2A 1670/4885PTGDR2 785/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | HTT 3512/4885KMT2A 1670/4885PTGDR2 785/4885 |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, PRKCH | HTT 3578/4885KMT2A 1690/4885PTGDR2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.